Portola Pharmaceuticals Inc (PTLA) Expected to Announce Quarterly Sales of $8.78 Million

Analysts expect that Portola Pharmaceuticals Inc (NASDAQ:PTLA) will post $8.78 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Portola Pharmaceuticals’ earnings. Portola Pharmaceuticals reported sales of $3.83 million during the same quarter last year, which suggests a positive year-over-year growth rate of 129.2%. The company is scheduled to report its next quarterly earnings results on Monday, November 5th.

According to Zacks, analysts expect that Portola Pharmaceuticals will report full-year sales of $30.61 million for the current year, with estimates ranging from $23.96 million to $35.59 million. For the next year, analysts expect that the company will report sales of $142.32 million per share, with estimates ranging from $91.45 million to $171.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Portola Pharmaceuticals.

Portola Pharmaceuticals (NASDAQ:PTLA) last released its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($1.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.49) by ($0.12). The firm had revenue of $4.01 million during the quarter, compared to the consensus estimate of $6.35 million. Portola Pharmaceuticals had a negative return on equity of 111.64% and a negative net margin of 1,503.29%. Portola Pharmaceuticals’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the business posted ($1.22) EPS.

PTLA has been the subject of several analyst reports. ValuEngine upgraded shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, May 29th. Oppenheimer set a $80.00 target price on shares of Portola Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, June 5th. Zacks Investment Research lowered shares of Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, July 19th. Cowen reiterated a “buy” rating on shares of Portola Pharmaceuticals in a report on Thursday, August 9th. Finally, Credit Suisse Group reiterated an “underperform” rating and set a $28.00 price objective (down previously from $49.00) on shares of Portola Pharmaceuticals in a report on Friday, August 10th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $52.17.

Shares of Portola Pharmaceuticals stock traded down $0.51 during trading on Tuesday, hitting $27.66. The stock had a trading volume of 32,196 shares, compared to its average volume of 1,332,152. The firm has a market capitalization of $1.89 billion, a PE ratio of -5.81 and a beta of 1.68. The company has a current ratio of 6.69, a quick ratio of 6.59 and a debt-to-equity ratio of 0.91. Portola Pharmaceuticals has a 12 month low of $24.63 and a 12 month high of $56.70.

In related news, Director Jeffrey W. Bird acquired 137,563 shares of the firm’s stock in a transaction that occurred on Tuesday, August 21st. The stock was bought at an average price of $25.17 per share, for a total transaction of $3,462,460.71. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jeffrey W. Bird acquired 390,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 23rd. The shares were bought at an average price of $25.84 per share, with a total value of $10,077,600.00. The disclosure for this purchase can be found here. Company insiders own 4.60% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its position in Portola Pharmaceuticals by 12.5% during the 2nd quarter. BlackRock Inc. now owns 5,251,512 shares of the biopharmaceutical company’s stock valued at $198,351,000 after purchasing an additional 583,581 shares during the period. Temasek Holdings Private Ltd increased its position in Portola Pharmaceuticals by 6.0% during the 2nd quarter. Temasek Holdings Private Ltd now owns 5,174,168 shares of the biopharmaceutical company’s stock valued at $195,428,000 after purchasing an additional 290,600 shares during the period. Cadian Capital Management LP increased its position in Portola Pharmaceuticals by 83.7% during the 2nd quarter. Cadian Capital Management LP now owns 2,280,201 shares of the biopharmaceutical company’s stock valued at $86,123,000 after purchasing an additional 1,039,257 shares during the period. Zevenbergen Capital Investments LLC increased its position in Portola Pharmaceuticals by 51.1% during the 2nd quarter. Zevenbergen Capital Investments LLC now owns 1,253,625 shares of the biopharmaceutical company’s stock valued at $47,349,000 after purchasing an additional 424,100 shares during the period. Finally, Kornitzer Capital Management Inc. KS increased its position in Portola Pharmaceuticals by 9.0% during the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 1,166,721 shares of the biopharmaceutical company’s stock valued at $44,067,000 after purchasing an additional 96,777 shares during the period. Institutional investors own 94.26% of the company’s stock.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers.

See Also: Index Funds

Get a free copy of the Zacks research report on Portola Pharmaceuticals (PTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply